National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 5) (PB 36 of 2019) (Cth)

Case

PB 36 of 2019

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 5)

National Health Act 1953

________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated      24 May   2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

  1. Name of Instrument

(1)This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 5).

(2)This Instrument may also be cited as PB 36 of 2019.

  1. Commencement

This Instrument commences on 1 June 2019.

  1. Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1     Amendments

  1. Schedule 1, after entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U.

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Powder for injection containing bleomycin sulfate 15,000 I.U. in 1 vial Injection Bleomycin for Injection, USP QY MP C6224 C6275 See Note 3 See Note 3 1 D(100)

  1. Schedule 1, entry for Captopril in the form Tablet 12.5 mg

(a)omit from the column headed “Schedule Equivalent” for the brand “Captopril Sandoz”: a

(b)omit:

a Zedace AF MP NP 90 5 90

  1. Schedule 1, entry for Ciprofloxacin in the form Tablet 250 mg (as hydrochloride)

 omit:

a Ciproxin 250 BN MP NP C5614 C5615 C5666 C5687 C5688 C5689 C5722 C5780 14 0 14

  1. Schedule 1, entry for Clindamycin in the form Capsule 150 mg (as hydrochloride)

(a)omit:

a Clindamycin-Link LI PDP C5487 24 0 24

(b)omit:

a Clindamycin-Link LI MP NP MW C5470 48 1 24

  1. Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg

(a)omit:

a Cyprone AF MP P5532 20
CN5532 		5
CN5532 		20

(b)omit:

a Cyprone AF MP 100 5 50

  1. Schedule 1, entry for Entecavir in the form Tablet 0.5 mg (as monohydrate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a ENTECAVIR APO GX MP C4993 C5036 60 5 30 D(100)

  1. Schedule 1, entry for Entecavir in the form Tablet 1 mg (as monohydrate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a ENTECAVIR APO GX MP C5037 C5044 60 5 30 D(100)

  1. Schedule 1, entry for Etanercept in the form Injection 50 mg in 1 mL single use auto-injector, 4 [Brand: Brenzys; Maximum Quantity: 1; Number of Repeats: 3]

(a)insert in numerical order in the column headed “Circumstances”: C7251

(b)insert in numerical order in the column headed “Circumstances”: C7289

(c)insert in numerical order in the column headed “Circumstances”: C8054

(d)insert in numerical order in the column headed “Circumstances”: C8103

(e)insert in numerical order in the column headed “Circumstances”: C8692

(f)insert in numerical order in the column headed “Circumstances”: C8839

(g)insert in numerical order in the column headed “Circumstances”: C8873

  1. Schedule 1, entry for Etanercept in the form Injection 50 mg in 1 mL single use auto-injector, 4 [Brand: Brenzys; Maximum Quantity: 1; Number of Repeats: 5]

(a)insert in numerical order in the column headed “Circumstances”: C7251

(b)insert in numerical order in the column headed “Circumstances”: C7289

(c)insert in numerical order in the column headed “Circumstances”: C8054

(d)insert in numerical order in the column headed “Circumstances”: C8103

(e)insert in numerical order in the column headed “Circumstances”: C8692

(f)insert in numerical order in the column headed “Circumstances”: C8839

(g)insert in numerical order in the column headed “Circumstances”: C8873

(h)insert in numerical order in the column headed “Purposes”: P7251

(i)insert in numerical order in the column headed “Purposes”: P7289 P8054

(j)insert in numerical order in the column headed “Purposes”: P8103

(k)insert in numerical order in the column headed “Purposes”: P8692

(l)insert in numerical order in the column headed “Purposes”: P8839

(m)insert in numerical order in the column headed “Purposes”: P8873

  1. Schedule 1, entry for Etanercept in the form Injections 50 mg in 1 mL single use pre-filled syringes, 4 [Brand: Brenzys; Maximum Quantity: 1;
    Number of Repeats: 3]

(a)insert in numerical order in the column headed “Circumstances”: C7251

(b)insert in numerical order in the column headed “Circumstances”: C7289

(c)insert in numerical order in the column headed “Circumstances”: C8054

(d)insert in numerical order in the column headed “Circumstances”: C8103

(e)insert in numerical order in the column headed “Circumstances”: C8692

(f)insert in numerical order in the column headed “Circumstances”: C8839

(g)insert in numerical order in the column headed “Circumstances”: C8873

  1. Schedule 1, entry for Etanercept in the form Injections 50 mg in 1 mL single use pre-filled syringes, 4 [Brand: Brenzys; Maximum Quantity: 1;
    Number of Repeats: 5]

(a)insert in numerical order in the column headed “Circumstances”: C7251

(b)insert in numerical order in the column headed “Circumstances”: C7289

(c)insert in numerical order in the column headed “Circumstances”: C8054

(d)insert in numerical order in the column headed “Circumstances”: C8103

(e)insert in numerical order in the column headed “Circumstances”: C8692

(f)insert in numerical order in the column headed “Circumstances”: C8839

(g)insert in numerical order in the column headed “Circumstances”: C8873

(h)insert in numerical order in the column headed “Purposes”: P7251

(i)insert in numerical order in the column headed “Purposes”: P7289 P8054

(j)insert in numerical order in the column headed “Purposes”: P8103

(k)insert in numerical order in the column headed “Purposes”: P8692

(l)insert in numerical order in the column headed “Purposes”: P8839

(m)insert in numerical order in the column headed “Purposes”: P8873

  1. Schedule 1, entry for Ethosuximide

substitute:

Ethosuximide Capsule 250 mg Oral Zarontin IX MP NP 200 2 100
MP NP 200 2 200
Oral solution 250 mg per 5 mL, 200 mL Oral Zarontin IX MP NP 1 5 1

  1. Schedule 1, entry for Fenofibrate

substitute:

Fenofibrate Tablet 48 mg Oral a FENOFIBRATE RBX RA MP NP 60 5 60
a Lipidil GO MP NP 60 5 60
a FENOFIBRATE RBX RA MP P7640 60 11 60
a Lipidil GO MP P7640 60 11 60
Tablet 145 mg Oral a FENOFIBRATE RBX RA MP NP 30 5 30
a Lipidil GO MP NP 30 5 30
a FENOFIBRATE RBX RA MP P7640 30 11 30
a Lipidil GO MP P7640 30 11 30

  1. Schedule 1, after entry for Ferric carboxymaltose in the form Injection 500 mg (iron) in 10 mL

insert:

Injection 1000 mg (iron) in 20 mL Injection Ferinject VL MP NP 1 1 1

  1. Schedule 1, entry for Filgrastim

(a)omit:

Injection 300 micrograms in 0.5 mL single use pre-filled syringe (TevaGrastim) Injection TevaGrastim TB MP C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 20 11 10 D(100)

(b)omit:

Injection 480 micrograms in 0.8 mL single use pre-filled syringe (TevaGrastim) Injection TevaGrastim TB MP C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 20 11 10 D(100)

  1. Schedule 1, entry for Fluticasone with salmeterol in the form Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)

(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a Pavtide GC MP NP C4930 1 5 1

(b)omit from the column headed “Responsible Person” for the brand “SalplusF Inhaler 125/25”: YC                               substitute: SZ

  1. Schedule 1, entry for Fluticasone with salmeterol in the form Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)

(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a Pavtide GC MP NP C4689 C4930 1 5 1

(b)omit from the column headed “Responsible Person”  for the brand “SalplusF Inhaler 250/25”: YC              substitute: SZ

  1. Schedule 1, entry for Gabapentin in the form Tablet 600 mg

 omit:

a Nupentin Tabs AF MP NP C4928 100 5 100

  1. Schedule 1, entry for Gabapentin in the form Tablet 800 mg

 omit:

a Nupentin Tabs AF MP NP C4928 100 5 100

  1. Schedule 1, entry for Guanfacine in each of the forms: Tablet 1 mg (as hydrochloride); Tablet 2 mg (as hydrochloride); Tablet 3 mg (as hydrochloride); and Tablet 4 mg (as hydrochloride)

(a)omit from the column headed “Circumstances”: C8564

(b)insert in numerical order in the column headed “Circumstances”: C9031 C9034

  1. Schedule 1, entry for Hydromorphone

omit:

Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 473 mL Oral Dilaudid MF PDP C4926 1 0 1
MP NP C4959 1 0 1

  1. Schedule 1, entry for Insulin aspart

insert as first entry:

Injection (human analogue) (fast acting) 100 units per mL, 10 mL vial Injection Fiasp NO MP NP 5 2 1

  1. Schedule 1, after entry for Insulin aspart in the form Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5

insert:

Injections (human analogue) (fast acting), pre-filled pen, 100 units per mL, 3 mL, 5 Injection Fiasp FlexTouch NO MP NP 5 1 1

  1. Schedule 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 10 mg

omit:

a Zircol AF MP NP 28 5 28

  1. Schedule 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 20 mg

omit:

a Zircol AF MP NP 28 5 28

  1. Schedule 1, entry for Modafinil

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a Modafinil GH GQ MP C6547 C8694 120 5 60

  1. Schedule 1, entry for Nilotinib in the form Capsule 200 mg (as hydrochloride monohydrate)

omit from the column headed “Circumstances”: C7024          

  1. Schedule 1, entry for Oxycodone in each of the forms: Capsule containing oxycodone hydrochloride 5 mg;and Capsule containing oxycodone hydrochloride 10 mg

(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a Oxycodone BNM LI PDP C4926 20 0 20
MP NP C4959 20 0 20

(b)insert in the column headed “Schedule Equivalent” for the brand “OxyNorm”: a

  1. Schedule 1, entry for Oxycodone in the form Capsule containing oxycodone hydrochloride 20 mg

(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a Oxycodone BNM LI MP NP C4959 20 0 20

(b)insert in the column headed “Schedule Equivalent” for the brand “OxyNorm”: a

  1. Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Brand: Pantoprazole APOTEX; Maximum Quantity: 30; Number of Repeats: 1]

insert in numerical order in the column headed “Circumstances”: C8776

  1. Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Brand: Pantoprazole APOTEX; Maximum Quantity: 30; Number of Repeats: 5]

(a)insert in numerical order in the column headed “Circumstances”: C8776

(b)insert in numerical order in the column headed “Purposes”: P8776

  1. Schedule 1, entry for Pemetrexed in the form Powder for I.V. infusion 100 mg (as disodium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pemetrexed SUN RA MP C4792 C7195 See Note 3 See Note 3 1 D(100)

  1. Schedule 1, entry for Pemetrexed in the form Powder for I.V. infusion 500 mg (as disodium)

(a)omit:

Pemetrexed Sandoz SZ MP C4792 C7195 See Note 3 See Note 3 1 D(100)

(b)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pemetrexed SUN RA MP C4792 C7195 See Note 3 See Note 3 1 D(100)

  1. Schedule 1, entry for Pemetrexed in the form Powder for I.V. infusion 1 g (as disodium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pemetrexed SUN RA MP C4792 C7195 See Note 3 See Note 3 1 D(100)

  1. Schedule 1, entry for Temozolomide in each of the forms: Capsule 5 mg; Capsule 20 mg; Capsule 100 mg; Capsule 140 mg; and Capsule 180 mg

(a)omit:

a Orion Temozolomide ON MP 5 5 5

(b)omit:

a Orion Temozolomide ON MP P4897 15 2 5

  1. Schedule 1, entry for Temozolomide in the form Capsule 250 mg

omit:

a Orion Temozolomide ON MP 5 5 5

  1. Schedule 1, entry for Teriflunomide in the form Tablet 14 mg

(a)insert in the column headed “Schedule Equivalent” for the brand “Aubagio”: a

(b)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a Teriflunomide Sandoz SZ MP C6854 C7741 28 5 28

  1. Schedule 1, entry for Tobramycin in the form Capsule containing powder for oral inhalation 28 mg (for use in podhaler)

omit from the column headed “Responsible Person”: NV       substitute: GO

  1. Schedule 1, entry for Tobramycin in the form Solution for inhalation 300 mg in 5 mL

omit from the column headed “Responsible Person” for the brand “Tobi”: NV                substitute: GO

  1. Schedule 1, entry for Tramadol in the form Tablet (sustained release) containing tramadol hydrochloride 100 mg

omit:

a Tramedo SR 100 AF MP NP C5822 20 0 20

  1. Schedule 1, entry for Tramadol in the form Tablet (sustained release) containing tramadol hydrochloride 150 mg

omit:

a Tramedo SR 150 AF MP NP C5822 20 0 20

  1. Schedule 1, entry for Tramadol in the form Tablet (sustained release) containing tramadol hydrochloride 200 mg

omit:

a Tramedo SR 200 AF MP NP C5822 20 0 20

  1. Schedule 1, entry for Ursodeoxycholic acid in the form Capsule 250 mg

omit from the column headed “Circumstances” (all instances): C5757               substitute: C9032

  1. Schedule 1, entry for Ursodeoxycholic acid in the form Tablet 500 mg

omit from the column headed “Circumstances”: C5757          substitute: C9032

  1. Schedule 3, after details relevant to Responsible Person code QH

insert:

QY Pro Pharmaceuticals Group Pty. Ltd. 20 605 457 430

  1. Schedule 3

omit:

YC Cipla Australia Pty Ltd 46 132 155 063

  1. Schedule 4, Part 1, entry for Blinatumomab

(a)omit from the column headed “Circumstances and Purposes” for circumstance code “C8949”: bllinatumomab                substitute: blinatumomab

(b)omit from the column headed “Circumstances and Purposes” for circumstance code ”C8966”: bllinatumomab                substitute: blinatumomab

  1. Schedule 4, Part 1, entry for Guanfacine

(a)omit:

C8564 Attention deficit hyperactivity disorder
Must be treated by a paediatrician or psychiatrist.
The condition must be or have been diagnosed according to the DSM-5 criteria; AND
Patient must have a contraindication to dexamfetamine, methylphenidate or lisdexamfetamine as specified in TGA-approved product information; OR
Patient must have a comorbid mood disorder that has developed or worsened as a result of dexamfetamine, methylphenidate or lisdexamfetamine treatment and is of a severity necessitating treatment withdrawal; OR
Patient must be at an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal if given a stimulant treatment with another agent; OR
Patient must have experienced adverse reactions of a severity necessitating permanent treatment withdrawal following treatment with dexamfetamine, methylphenidate and lisdexamfetamine (not simultaneously).
Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive. 		Compliance with Authority Required procedures - Streamlined Authority Code 8564

(b)insert in numerical order after existing text:

C9031 Attention deficit hyperactivity disorder
Continuing treatment
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Patient must have a contraindication to dexamfetamine, methylphenidate or lisdexamfetamine as specified in TGA-approved product information; OR
Patient must have a comorbid mood disorder that has developed or worsened as a result of dexamfetamine, methylphenidate or lisdexamfetamine treatment and is of a severity necessitating treatment withdrawal; OR
Patient must be at an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal if given a stimulant treatment with another agent; OR
Patient must have experienced adverse reactions of a severity necessitating permanent treatment withdrawal following treatment with dexamfetamine, methylphenidate and lisdexamfetamine (not simultaneously). 		Compliance with Authority Required procedures - Streamlined Authority Code 9031
C9034 Attention deficit hyperactivity disorder
Initial treatment
Must be treated by a paediatrician or psychiatrist.
The condition must be or have been diagnosed according to the DSM-5 criteria; AND
Patient must have a contraindication to dexamfetamine, methylphenidate or lisdexamfetamine as specified in TGA-approved product information; OR
Patient must have a comorbid mood disorder that has developed or worsened as a result of dexamfetamine, methylphenidate or lisdexamfetamine treatment and is of a severity necessitating treatment withdrawal; OR
Patient must be at an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal if given a stimulant treatment with another agent; OR
Patient must have experienced adverse reactions of a severity necessitating permanent treatment withdrawal following treatment with dexamfetamine, methylphenidate and lisdexamfetamine (not simultaneously).
Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive. 		Compliance with Authority Required procedures - Streamlined Authority Code 9034

  1. Schedule 4, Part 1, entry for Nilotinib

omit:

C7024 Chronic Myeloid Leukaemia (CML)
The condition must be in the chronic phase; OR
The condition must be in the accelerated phase; AND
Patient must have failed an adequate trial of PBS-subsidised first line treatment with imatinib for this condition; OR
Patient must have failed an adequate trial of PBS-subsidised first line treatment with dasatinib for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
Failure of an adequate trial of imatinib or dasatinib is defined as:(i) Lack of response to initial imatinib or dasatinib therapy, defined as either:- failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or dasatinib for patients initially treated in chronic phase; or- failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or dasatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or- failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib or dasatinib; OR(ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or dasatinib therapy; OR(iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or dasatinib therapy; OR(iv) Development of accelerated phase in a patient previously prescribed imatinib or dasatinib for the chronic phase of chronic myeloid leukaemia.
Accelerated phase is defined by the presence of 1 or more of the following:(1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or(2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or(3) Peripheral basophils greater than or equal to 20%; or(4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or(5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR(v) Disease progression (defined as a greater than or equal to.50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or dasatinib therapy in patients with accelerated phase chronic myeloid leukaemia, provided that blast crisis has been excluded on bone marrow biopsy.
Patients should be commenced on a dose of nilotinib of 400 mg twice daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to nilotinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.
Applications for authorisation must be in writing and must include:(a) a completed authority prescription form; and(b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and(c) a signed patient acknowledgement; and(d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and(e) where there has been a loss of response to imatinib or dasatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement. 		Compliance with Authority Required procedures

  1. Schedule 4, Part 1, entry for Somatropin

(a)omit from the column headed “Circumstances and Purposes” for circumstance code “C8407”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

(b)omit from the column headed “Circumstances and Purposes” for circumstance code “C8423”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

(c)omit from the column headed “Circumstances and Purposes” for circumstance code “C8433”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

(d)omit from the column headed “Circumstances and Purposes” for circumstance code “C8439”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

(e)omit from the column headed “Circumstances and Purposes” for circumstance code “C8452” (all instances): 7.5mg/m2/week                substitute: 7.5mg/m2/week

(f)omit from the column headed “Circumstances and Purposes” for circumstance code “C8468” (all instances): 7.5mg/m2/week                substitute: 7.5mg/m2/week

(g)omit from the column headed “Circumstances and Purposes” for circumstance code “C8472”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

(h)omit from the column headed “Circumstances and Purposes” for circumstance code “C8494”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

(i)omit from the column headed “Circumstances and Purposes” for circumstance code “C8503”: 30mL/minute/1.73m2                substitute: 30mL/minute/1.73m2

  1. Schedule 4, Part 1, entry for Ursodeoxycholic acid

substitute:

Ursodeoxycholic acid C9032 Primary biliary cholangitis (previously known as Primary biliary cirrhosis) Compliance with Authority Required procedures - Streamlined Authority Code 9032
Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0